펠토스 테라퓨틱스(PTHS)는 NYSE MKT에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $22.41 (+0.13%), 시가총액 $0.09B, 52주 최저~최고 $0.93 ~ $37.42.
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly kn
펠토스 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
펠토스 테라퓨틱스의 현재 주가는 $22.41 (+0.13%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
펠토스 테라퓨틱스의 시가총액은 약 $0.09B입니다.
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment o